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STuned using the frequency analyser (HM5014-2) to the corresponding Larmor
frequency of 64MHz for 1.5T MRI (GE, Signa), occluders were implanted into
a freshly excised porcine heart and Thiel soft embalmed human heart under MRI
guidance. 0.9% NaCl solution bath was used as the medium. Two MRI resonant
markers were placed on the delivery system to position the occluders with the right
orientation. Real time sequences were used for the visualization during the implan-
tation (MS, FGRE, TR¼10 ms-50 ms, TE¼2.4 ms-4 ms and small ﬂip angles of 15-30
with standard head coil). To keep the hearts in the right orientation, a holding device
made of acrylic plates was manufactured.
Results: The in-vitro test results showed a local image contrast enhancement of up to
4 times at low ﬂip angles of about 10-15. The locally improved contrast in the MR
images was relative homogenous and showed no artefacts. The MRI guided
implantation in both fresh porcine and Thiel soft embalmed human hearts was
successful. The MRI resonant markers on the delivery system enabled the correct
positioning of the occluders. An exact differentiation between the MR-Enhancing
implant and tissue were obtained in all views.
Conclusions: MRI guided implantation of occluders can be improved with resonant
circuits integrated into the design of the implant. The locally enhanced MRI signal
creates a better contrast between the tissue and the implant and enables accurate MRI
guided delivery, and non-invasive follow up examination.TCT-815
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Background: Pathology studies have shown correlation between positive vascular
remodeling and plaque characteristics in humans. In this study we aimed to correlate
the presence of in vivo vascular remodeling with the presence of histological features
of plaque vulnerability in the novel familial hypercholesterolemic swine (FHS) model
of atherosclerosis.
Methods: Fifteen naïve coronary arteries of 3-year-old FHS were imaged with
angiography and intravascular ultrasound (IVUS) to identify native plaques.
Remodeling index (RI) was deﬁned as the area of the external elastic lamina (EEL)
within the plaque divided by the EEL in the proximal reference by IVUS. Analyzed
plaques were allocated into positive (RI >1.0) and negative remodeling (RI  1.0)
categories. After imaging, coronaries were harvested and sectioned every 3-5 mm
intervals. Each section was stained with Movat's pentachrome stain and evaluated for
complex atherosclerotic features such as calciﬁcation, plaque hemorrhage and necrotic
core.
Results: Twenty three plaques were found and 43% (n¼10) displayed positive remod-
eling. Percent diameter of stenosis did not show signiﬁcant difference between plaques
with positive or negative remodeling (RI>1.0, 55.722.0 % versus RI1.0, 45.520.0
%, p¼0.3). Histological comparison revealed plaqueswith positive remodeling contained
higher incidence of necrotic core (RI>1.0, 90% versus RI1.0, 46.1% p¼0.03), necrotic
core area (RI>1.0, 2.230.6 mm2 versus RI1.0, 1.340.7 mm2, p¼0.03), and thinner
ﬁbrous cap (RI>1.0, 172102mmversusRI1.0, 312129mm,p¼0.023) thanplaques
with negative remodeling. Plaque hemorrhage (RI>1.0, 40 % versus RI 1.0, 0 %
p¼0.02) and calciﬁcation (RI>1.0, 60 % versus RI1.0, 15.3 % p¼0.03) was also more
frequently observed in plaques with positive remodeling.
Conclusions: The FHS model displays human-like vascular remodeling features.
Alike in humans, these features correlate to histopathological characteristics of plaque
vulnerability.TCT-816
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Background: Pre-clinical studies of transcatheter aortic valve implantation (TAVI)
systems have traditionally been conducted on surgically implanted valves in the mitral
position or on valves placed in the descending aorta. Very limited data exist on
orthotopic TAVI utilizing animal models.
Methods: Cardiac and aortic anatomy of juvenile-adolescent Dorset sheep was
determined with 3D reconstruction of CT-scan images. Animals with appropriateJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrmeasurements were selected for transfemoral TAVI with a 27mm Lotus Valve
System (Boston Scientiﬁc, Natick, US). Procedural guidance combined intracardiac
echocardiography (ICE) and ﬂuoroscopy. Valve performance was assessed at implant
(ICE) and 90 days (transthoracic echocardiography [TTE])
Results: Valve deployment was attempted on 15 animals. Successful implantation
with >72h survival was achieved in 80% of the cases (12/15). One sheep was
survived to 7 days, 3 to 30 days and 8 to 140 days (73% scheduled survival rate [11/
15]). Complete AV block was observed in 2 cases. Immediate post-implantation valve
evaluation revealed: no paravalvular leak (PVL) in 92% (12/13), mild PVL in one case
and normal function with a mean mean transvalvular gradient of 4.1 mmHg (range 1.2
to 7.7 mmHg). Ninety-day TTE showed a mean mean gradient of 29.1 mmHg (range
13.5 to 47.0 mmHg). Animals gained an average 5.1kg per month during follow-up.
Histology showed no endocarditis and minimal inﬂammation at 30 days (140 day data
pending).
Conclusions: Chronic survival rate in this non-diseased ovine model was excellent.
To our knowledge this represents the ﬁrst description of successful TAVI in the
native aortic position in a chronic animal study. The Lotus valve's fully reposi-
tionable design allowed precise positioning and provided adequate performance at
90 days. Adolescent and juvenile sheep are well-known models of accelerated
bioprostheses calciﬁcation which, combined with signiﬁcant animal growth, likely
explain the increase in mean gradient at follow-up. Long term (140 day) histology
will provide relevant insight on valve behaviour in this novel animal model of
orthotopic TAVI.TCT-817
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Background: Cardiac gene therapy represents one of the future therapeutic strategies
for cardiomyopathy but methods and measures of efﬁcacy vary widely. The aim of
this current study was to test an antegrade coronary approach for AAV9 delivery in
combination with vasodilators and concomitant retrograde blockage of the coronary
sinus in a pre-clinical large animal model.
Methods: The approach was tested in 14 chronically instrumented dogs which
received the vector intracoronarily. The left main coronary artery was cannulated with
a 5F EBU 3.5 or C1 catheter and a 2.5F micro-infusion catheter was selectively
advanced into the target vessel. The solution for infusion was prepared with 10^13
AAV9-GFP particles, saline, SubstanceP (0.25ng/kg/min) and Adenosine (0.15mg/kg/
min) and injected slowly over 20min. To further enhance endothelial penetration
nitrogycerine was given i.v. (1mg/kg/min). The coronary sinus was approached with
a custom made balloon in seven subjects which was inﬂated during the infusion.
Hemodynamic data were recorded during the procedure and infection efﬁcacy was
assessed using immunohistochemistry after 30days.
Results: The procedure was successful in all cases. Procedure time was signiﬁcantly
longer in the cases with coronary sinus occlusion (5812 vs. 9348min, p<0.05).
Mean arterial pressure (MAP) and dP/dtmax dropped in all cases (11617 to
4919mmHg and 2332487 to 1466454mmHg/sec) whereas the mean coronary
ﬂow increased from 146 to 187mL/min. These effects were enhanced with
coronary sinus blockage where infusion had to be discontinued during the procedure
several times in three cases due to hypotension (MAP 40mmHg11mmHg with and
599mmHg without coronary sinus blockage). The GFP-transduction rate was
heterogeneous within the myocardial layers (0.5-55%). There was no signiﬁcant
increase of GFP-expression caused by the additional coronary sinus blockage
(p¼0.08).
Conclusions: Antegrade intracoronary gene delivery is feasible, comparatively
effective and can be enhanced with vasodilators. The addition of coronary sinus
blockage during infusion increases the complexity and risk of the procedure in some
cases and might not be translatable for heart failure patients.TCT-818
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Background: Atherosclerosis seems to affect arteries in a site-speciﬁc pattern.
Remodeling processes, frequency of acute thrombotic complications and restenosis-
rates differ in various vascular beds. For a better understanding of site-speciﬁc
differences we analyzed plaque morphology and gene expression in femoral, carotid
and coronary arteries.
Methods: Coronary vessels were obtained from 16 patients with coronary artery
disease, carotid arteries from 10 and femoral arteries from 9 patients with
peripheral occlusive disease (PAD). Microscopic sections were analyzed blindly onacts/POSTER/Basic Science, Animal Models, and Cell Therapy B247







Sa semiquantitative scale after the following stainings: hematoxylin eosin (for
assessment of intra- and extracellular lipids and for assessment of thrombus
formation), Elastica van Gieson, anti-CD31 for assessment of vessel density, anti-
CD68, anti-CD3 and anti-CD15 for analysis of local inﬂammation, anti-SMC actin
to stain smooth muscle cells, anti-CD61 for platelet depositions, TUNEL staining
for apoptotic cells.
Results: Lipid and foam cell content was most pronounced in aortic lesions (P¼0.02,
P¼0.04), calciﬁcation and SMC actin in femoral lesions (P¼0.001, P¼0.001), CD3+
cells in carotid lesions (P¼0.004) and TUNEL+ apoptotic cells in coronary lesions
(P¼0.01). Thrombus was most prevalent in carotid and aortic lesions (P¼0.02).
Neutrophil (CD15+) and monocyte (CD68+) cell inﬁltrations as well as vessel density
were most pronounced in carotid and femoral lesions (P¼0.04, P¼0.02, P¼0.005). No
signiﬁcant changes were observed in vessel hemorrhage or platelet content. These
results suggest more inﬂammatory lesions in carotid and femoral arteries with an
increase in calciﬁcation and SMC content in femoral lesions as compared to more lipid
rich lesions within the aorta and an increase in apoptotic cells within coronary lesions.
Additionally, gene expression of atherosclerosis related genes in carotid and femoral
endaterectomy specimen was measured. An overall increased metabolism was found
in femoral plaques, especially genes concerning inﬂammatory response, response to
stress, apoptosis, adhesion, whereas in carotid lesions, we detected overexpression of
genes related to lipid/cholesterol transport and metabolism and negative transcription
regulators.
Conclusions: Different arterial territories are differently affected by atherosclerosis:
Our results suggest more inﬂammatory lesions in carotid and femoral arteries with an
increase in calciﬁcation and SMC content in femoral lesions as compared to more lipid
rich lesions within the aorta and an increase in apoptotic cells within coronary lesions.
Concerning PAD, gene expression in atherosclerotic lesions shows signiﬁcant
differences. Understanding of the local differences of atherosclerosis may aid to
improve prevention and lead to targeted treatment of atherosclerosis and its
complicationsTCT-819
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Background: The Combo Dual Therapy stent (OrbusNeich Medical, Ft. Lauderdale,
FL) combines anti-proliferative abluminal sirolimus elution from a bioresorbable
matrix with luminal CD34 antibody endothelial progenitor cell capture. This study
compares the healing of the Combo stent to an everolimus-eluting stent [EES] (Xience
Prime; Abbott Vascular, Santa Clara, CA), along with the Genous stent (OrbusNeich)
as control.
Methods: 31 atherosclerotic rabbits were implanted with bilateral iliac stents and
survived for 28 days or 45 days. Select animals underwent assessment by OCT after
stent implant and again prior to sacriﬁce. To assess cellular proliferation, animals were
given BrdU before sacriﬁce. The stented arterial segments were designated for either
light microscopy evaluation or en face assessment by both SEM for endothelial
coverage and immuno confocal microscopy for expression of endothelial markers
CD31/PECAM and eNOS.
Results: At 28 days, morphometric comparison of areas measurements showed
statistically comparable EEL, IEL, lumen, stent, media, and plaque areas and
thicknesses between groups. Uncovered struts were seen in all groups with the
highest and statistically signiﬁcant frequency in EES > Combo > Genous. At
45 days, morphometric values remained relatively similar to day 28 with a slight
increase of stenosis seen with Genous. Endothelial coverage at 28 days above
struts by SEM was highest in Genous (98.3%), followed by Combo (83.3%),
and lowest in EES (52.7%) (p¼0.025). Endothelial coverage between struts was
nearly identical (Combo 93.3%, Genous 87.5%, EES 92.0%, p¼0.714). By
OCT, 28-day animals showed less area stenosis and less neointimal thickness in
Combo and EES as compared to Genous. There were no signiﬁcant differences
between Combo and EES in terms of area stenosis, neointimal thickness, and
uncovered struts. No stents showed thrombosis or restenosis at both 28-day and
45-day time points. The OCT analysis correlated signiﬁcantly with histologic
ﬁndings.
Conclusions: Compared to the EES stent, the Combo stent was found to have
a similar reduction in neointimal proliferation, while exhibiting fewer uncovered struts
and signiﬁcantly greater endothelial coverage over struts.B248 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 jTCT-820
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Background: Increased expression of interferon (IFN)-beta was shown in patients
with insufﬁcient coronary collaterals. Furthermore, mice treated with IFN-beta
demonstrate inhibition of collateral artery growth (arteriogenesis). Interestingly,
type I interferons (IFN-alpha and IFN-beta) have been identiﬁed as proathero-
sclerotic cytokines and in mouse models of atherosclerosis, IFN-beta treatment
accelerated lesion formation and increased accumulation of macrophages in
plaques. We hypothesized that arteriogenesis can be stimulated using monoclonal
antibodies inhibiting IFN-beta signaling without accelerating atherosclerosis.
Methods: In an atherosclerotic murine hindlimb-ischemia model, LDLR-/- mice were
treated during a 4-week period with monoclonal antibodies speciﬁc for mouse
Interferon-alpha/beta Receptor subunit 1 (IFNAR-1) or murine IgG isotype as control.
Hindlimb perfusion was measured using laser Doppler perfusion imaging (LDPI)
directly after femoral artery ligation as well as at 2, 7, 14 and 28 days following
ligation. We used a disease model to investigate effects of anti-IFNAR-1 on athero-
sclerosis, which was evaluated with histology to determine plaque area and
composition.
Results: Hindlimb perfusion restoration after femoral artery ligation was improved
in mice treated with anti-IFNAR-1 compared to controls as assessed by LDPI after
7, 14 and 28 days (treatment vs. control; 7 days: 35.6  16.5% vs. 23.6  8.7%,
p¼0.027; 14 days: 51.4  17.2% vs. 35.0  12.3%, p 0.010; 28 days 71.5  13.8%
vs. 54.0  16.3%, p¼0.005). Total plaque area (treatment vs. control: 118.8 
46.1x103 mm2 vs. 139.3  46.5 x103 mm2, p¼0.275) as well as composition were
unaffected.
Conclusions: Blocking IFNAR-1 using monoclonal antibodies stimulates collateral
artery growth in mice and has a neutral effect on atherosclerosis.TCT-821
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Background: The REVIVAL-2 study showed that stem cell mobilization by G-CSF
does not inﬂuence infarct size, left ventricular function and coronary restenosis in
patients with AMI that underwent successful percutaneous coronary intervention
(PCI). The objective of the present analysis was to assess the impact of G-CSF
treatment on 5-year clinical outcomes from the REVIVAL-2 trial.
Methods: In the randomized, double-blind, placebo-controlled REVIVAL-2 study,
114 patients with the diagnosis of acute myocardial infarction were enrolled 5 days
after successful reperfusion by percutaneous coronary intervention. Patients were
assigned to receive 10 mg/kg G-CSF (56 patients) or placebo (58 patients) for 5 days.
The primary outcome for this analysis was the composite of death, myocardial
infarction or stroke 5 years after randomization.
Results: The endpoint occurred in 7.1% of patients in the G-CSF group versus
15.5% assigned to placebo (relative risk [RR], 0.5; 95% conﬁdence interval [CI],
0.1-1.4; p¼0.17). The combined incidence of death or myocardial infarction
occurred in 5.4% of the patients assigned to G-CSF and 13.8% of the patients
assigned to placebo (RR, 0.4; 95% CI, 0.1-1.4; p¼0.14). The major driver was
mortality which was reduced from 10.3% in the placebo group to 3.6% in the
G-CSF group (p¼0.16).
Conclusions: These long term follow-up data show that G-CSF may reduce
adverse events especially mortality in patients with acute myocardial infarction.
ClinicalTrials.gov Identiﬁer: NCT00126100TCT-822
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Background: The selective VEGFR-1 activator VEGF-B has been shown to
be antiapoptotic and cytoprotective in absence of angiogenic side effects. ThusTCT Abstracts/POSTER/Basic Science, Animal Models, and Cell Therapy
